Featured in STEM CELLS

Skip slideshow

Browse Articles

Open access

Bone‐forming perivascular cells: Cellular heterogeneity and use for tissue repair

  •  12 July 2021

Abstract

Mesenchymal progenitor cells in the tunica adventitia have a hierarchy of differentiation and proliferation potential. On top of the hierarchy, platelet-derived growth factor receptor (PDGFR)α+ and aldehyde dehydrogenase (ALDH)High cells show a bipotent differentiation potential into osteogenic and adipogenic cell lineages with high proliferative rate. Conversely, CD10 and CD107a expression separate osteogenic progenitors from adipogenic progenitors, respectively. Moreover, osteoprogenitors can transition into adipogenic phenotype.
free access

CORRIGENDUM

  •  5 July 2021
No abstract is available for this article.

Hematopoietic stem cell‐derived functional osteoblasts exhibit therapeutic efficacy in a murine model of Osteogenesis imperfecta

  •  5 July 2021

Abstract

Transplantation (Tp) of hematopoietic stem cells (HSCs) in Osteogenesis imperfecta (OI) mice causes replacement of mutated osteoblasts with normal osteoblasts (derived from HSCs) that lay down normal collagen and result in clinical improvements.

Two DNA binding domains of MGA act in combination to suppress ectopic activation of meiosis‐related genes in mouse embryonic stem cells

  •  5 July 2021

Abstract

MGA bearing two distinct DNA-binding domains is a scaffolding component of PRC1.6 that prevents precocious and ectopic onset of meiosis in germ cells and embryonic stem cells (ESCs), respectively. Here, we demonstrate that both Mga domains repress distinct sets of meiosis-related genes in ESCs. Our data also identified Meiosin as a linchpin molecule between positive and negative regulations of meiotic onset.

Cytokine and epigenetic regulation of programmed death‐ligand 1 in stem cell differentiation and cancer cell plasticity

  •  28 June 2021

Abstract

SOX2-mediated reprogramming of fibroblasts or cancer plasticity of lung cancer cells inhibits programmed death-ligand 1 (PD-L1) expression (upper). SOX2 expression is negatively associated with PD-L1 as well as HBEGF/EGFR and TGF-β signaling molecules (middle). SOX2 interacts with HDAC1, which silences PD-L1 expression (lower left). TGF-β induces PD-L1 expression via MEK pathway, while HBEGF/EGFR enhances PD-L1 expression through MEK and AKT pathways (lower right).
Open access

DUSP5 promotes osteogenic differentiation through SCP1/2‐dependent phosphorylation of SMAD1

  •  24 June 2021

Abstract

DUSP5 promotes the osteogenic differentiation of mesenchymal stromal cells (MSCs) by repressing SMAD1 signaling pathway in a SCP1/2-dependent manner. The linker region of DUSP5 occupies the phosphatase domain of SCP1/2 and thereby releases the inhibitory effect of SCP1/2 on SMAD1 signaling. Additionally, Dusp5 overexpression could effectively ameliorate osteopenia of mice.
Open access

SARS‐CoV‐2 infects an upper airway model derived from induced pluripotent stem cells

  •  21 June 2021

Abstract

We have developed a protocol to generate airway epithelial basal-like cells from induced pluripotent stem cells, which simplifies the manufacture of cellular models of the human upper airways that are capable of supporting SARS-CoV-2 infection/replication and the secretion of cytokines in a manner similar to that of in vivo airways.
Open access

Human placenta mesenchymal stem cell protection in ischemic stroke is angiotensin converting enzyme‐2 and masR receptor‐dependent

  •  14 June 2021

Abstract

Angiotensin converting enzyme-2 (ACE-2) contributes to human placenta mesenchymal stem cell (hPMSC)-induced protection against ischemic injury through MasR pathway.
Open access

Mitochondria in neurogenesis: Implications for mitochondrial diseases

  •  5 June 2021

Abstract

During healthy neurogenesis, there is an orchestrated programming of energy metabolism, which transits from glycolysis toward oxidative phosphorylation (OXPHOS). In mitochondrial diseases, neural progenitor cells (NPCs) may fail to acquire an OXPHOS profile, leading to impaired generation and maturation of neurons. NPC metabolism may thus represent a potential target of interventions for mitochondrial neurological diseases.
Open access

Zbtb46‐dependent altered developmental program in embryonic stem cell‐derived blood cell progenitors

  •  31 May 2021

Abstract

In this study, we engineered murine Zbtb46-inducible embryonic stem cell lines and characterize their hematopoietic differentiation capacity. We found here that enforced expression of Zbtb46 strongly suppressed the myeloid blood cell development; moreover, this transcription factor negatively influenced the cell proliferation. On the other hand, ectopic expression of Zbtb46 was coupled with the enhanced production of CD105+ cells and the augmented erythroid blood cell development.
more >

Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress

  •  14 July 2021

Abstract

Prostacyclin/prostaglandin I2 (PGI2) is a novel hematopoietic stem cell (HSC) regulatory factor enriched at the endosteum, synthesized by its synthase PTGIS expressed mainly on osteoblasts (OB), followed by mesenchymal stromal cells (MSC) and endothelial cells (EC). Ex vivo and in vivo treatment with PGI2 analogues enhance HSC long-term competitive repopulation potential and protect reconstituting HSC from stress.

Bone marrow‐derived progenitor cells contribute to remodeling of the postpartum uterus

  •  5 July 2021

Abstract

Bone marrow-derived stem cells (BMDSC) are mobilized to the circulation and get recruited to the uterus in the postpartum period where they contribute to various nonhematopoietic endometrial cell populations as part of the process of cellular turnover and regeneration. They differentiate into stromal cells, endothelial cells (EC) and epithelial cells, actively participating in uterine tissue remodeling.
free access

Organoid Technology: Current Standing and Future Perspectives

  •  30 March 2021

Abstract

Organoid generation and therapeutic potential
more >
more >
free access

Concise Review: Mesenchymal Stem Cells: From Roots to Boost

  • STEM CELLS
  •  855-864
  •  12 April 2019

Abstract

Mesenchymal stem cells: from isolation to transplantation.
Open access

Pluripotent stem cell‐derived retinal organoids for disease modeling and development of therapies

  • STEM CELLS
  •  1206-1215
  •  7 June 2020

Abstract

Retinal organoids offer a unique human model system to study mechanisms of disease pathogenesis and for developing therapies.
free access

Restoring aged stem cell functionality: Current progress and future directions

  • STEM CELLS
  •  1060-1077
  •  30 May 2020

Abstract

Possibly, combination of treatments may allow for more universal benefits encompassing many stem cell compartments.
free access

Stem cell homing: From physiology to therapeutics

  • STEM CELLS
  •  1241-1253
  •  11 June 2020

Abstract

Steps in hematopoietic stem cell (HSC) homing and egress to and from marrow. Homing (left hand panel) occurs in the marrow sinusoidal endothelium. (1) Selectin-mediated braking or rolling occurs. Selectins involved include P-selectin which interacts with CD162 and SLex, and E-selectin which recognizes CD15, SLex, and CD162 on stem cells. (2) HSCs migrate on adhesion ligands presented by the vascular endothelium, so-called tethering. This involves CD49d-f, CD11b, and CD11c on the hematopoietic stem and progenitor cells and CD106/fibronectin, laminin, and ICAM-1 on endothelium as well as numerous other adhesion receptors and their ligands. (3) Changes in integrin conformation facilitate tight adhesion to the endothelial cell. (4) The stem cell then migrates through the endothelial cell cytoplasm or paracellularly. The cell will then migrate through matrix to reach the lodging destination. This is facilitated by CXCL12, c-kit ligand, cathepsins, and matrix metalloproteinases. Egress (right hand panel) involves: (1) Matrix transmigration in response to chemokine and growth factor effects. Matrix components involved include collagen IV, laminin, fibronectin, hyaluronic acid, and tenascin; among others. (2) Trans-endothelial migration, and (3) Cell release with disruption of receptor/ligand interactions such as those between between CXCL12 and CXCR4 or CD49d and CD106 (VCAM-1).
Open access

Concise Review: Human Embryonic Stem Cells—What Have We Done? What Are We Doing? Where Are We Going?

  • STEM CELLS
  •  17-25
  •  28 June 2016

Abstract

Ethical issues, the regulatory landscape, and the limited spectrum of diseases were all drawbacks of hESC lines that hiPSC did not have. It is to expect that in foreseeable future hiPSC will take over hESC in both research and clinical applications.

Latest news